NOVO NORDISK A S (NVO)
Global healthcare leader pioneering breakthrough diabetes and chronic disease treatments with heritage spanning a century.
What NOVO NORDISK A S does
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark, with a primary focus on defeating serious chronic diseases built upon its heritage in diabetes. The company drives change through pioneering scientific breakthroughs, expanding access to its medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs approximately 68,800 people across 80 countries and markets its products in around 170 countries worldwide.
Themes: GLP-1 / diabetes, obesity / weight management, chronic disease management, pharmaceutical innovation, global healthcare access
Fundamentals
- Price$50.32 as of 2026-07-17 close
- Market cap$1.12T as of 2026-07-20
- 1-year return-23.8% as of 2026-07-17 close
- P/E9.17 as of 2026-07-20
- Net margin+37.2% as of 2026-07-20
- Gross margin+81.8% as of 2026-07-20
- ROE+66.4% as of 2026-07-20
- Debt / equity0.72 as of 2026-07-20
- Revenue growth (YoY)+8.1% as of 2026-07-20
- Beta1.85 as of 2026-07-20
Dividend: yield +3.5%; pays a dividend.
Key risks (from latest filing)
["Regulatory and approval risks for new drug candidates and indications","Competitive pressure in diabetes and obesity treatment markets, particularly from GLP-1 agonist competitors","Currency and international market exposure risks across 170 countries"]
Competitors & peers
- Eli Lilly (LLY)
- Roche (RHHVF)
- Sanofi (SNFXF)
- AstraZeneca (AZN)
- Merck (MRK)
- Amgen (AMGN)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
NOVO NORDISK A S is found in…
NVO ranks in…
Frequently asked questions
What does NOVO NORDISK A S (NVO) do?
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark, with a primary focus on defeating serious chronic diseases built upon its heritage in diabetes. The company drives change through pioneering scientific breakthroughs, expanding access to its medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs approximately 68,800 people across 80 countries and markets its products in around 170 countries worldwide.
Does NVO pay a dividend?
Yes — NOVO NORDISK A S (NVO) pays a dividend, with an indicated yield of about 3.55% (Finnhub, as of 2026-07-20). Informational only — not financial advice.
Who are NOVO NORDISK A S's (NVO) competitors?
Notable peers of NOVO NORDISK A S (NVO) include Eli Lilly, Roche, Sanofi, AstraZeneca and Merck. This peer set is informational only — not financial advice.
Where does stocks-llm's data on NVO come from?
Fundamentals and prices come from Finnhub, as of 2026-07-20; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: Finnhub, as of 2026-07-20. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-17.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.